Kornimate/medical-research-clean huggingface dataset:
blood pressure (bp) visit intensification study

Conditions: Blood Pressure; Hypertension

Summary: aim 1: the purpose of the study is to implement the seventh joint national committee on the diagnosis, prevention and treatment of hypertension (jnc vii) recommendation for monthly visits for hypertensive patients with uncontrolled blood pressure (bp) using a theoretically-informed, empirically grounded, multimodal quality improvement (qi) intervention. aim 2: to improve bp control and reduce disparity in bp through implementation of monthly visits. aim 3: to assess potential mediators and moderators of the intervention.

this study is a stepped wedged cluster randomized trial designed to improve management of uncontrolled blood pressure among patients in federally qualified health centers through the auspices of the the clinical directors network practice-based research network (cdn pbrn).

Eligibility criteria:
inclusion criteria: * federally qualified health center in the clinic directors network, practice champion, electronic medical record system exclusion criteria: * clinicians who have been at the practice less than 6 months, practices planning to change electronic medical record systems within the next 6 months
comparison study of 'virtual teacher' support for rehabilitation after stroke.

Conditions: Stroke

Summary: the aim of the project is to assess whether the continuous visualization of on-line teacher in virtual reality (vr) is effective for the improvement of upper limb motor function, in stroke patients.

a single-blind randomized controlled trial (rct) will be carried out to compare the effects of reinforced feedback in virtual environment (rfve) treatment with continuous displaying of a virtual teacher (ever teacher group) with rfve without the presence of a virtual teacher (never teacher group).

Eligibility criteria:
inclusion criteria: * first single stroke, * absence of ideomotor apraxia, neglect, aphasia interfering with verbal comprehension, * 0 \< nihss-it \< 4 exclusion criteria: * bilateral or cerebellum stroke, * unstable medical conditions, * fracture, * major depressive disorders, * other neurological conditions, * epilepsy.

Keywords: virtual reality, enhanced feedback, stroke, rehabilitation, motor learning
assessment of injectable medication platforms

Conditions: Overdose Antidote; Bleeding; Allergic Reaction

Summary: background: while medical advances for in-hospital care rapidly evolve, a mainstay of effective pre-hospital care remains the ability to treat medical emergencies such as anaphylaxis, prolonged seizure, overdose, or uncontrolled bleeding, through rapid administration of appropriate medication. autoinjectors are used globally to deliver medications in a timely manner, often in environments where immediate access to medical facilities is limited. rapid administration of intramuscular medication delivery is essential where oral or intravenous delivery is either not possible or ineffective. the purpose of the proposed study seeks to determine the efficiency various types of medication injection administration.

research objective: to understand the efficiency of injectable medication delivery in the canadian forces and civilian world for improved care delivery in military and pre-hospital environments. participants: approximately thirty (30) participants will be recruited for the study. methods: data will be obtained on the technical comparison of efficiency for pre-filled syringes to the current standards of administration. the timing and accuracy for administering saline to an inanimate object using the traditional methods versus a pre-filled medication syringes will be compared. risks and risk mitigation: the participants in this study are all practicing military personnel who are able to give free and informed consent. to reduce undue influence, lcol meredith and dr gupta will not be involved in recruitment. as a result, these participants are a low vulnerability group. the risk of any adverse events is low since data scenarios, and participants may choose to skip any questions or scenarios that participants do not wish to do. investigators will remind all participants that their participation is voluntary, and that they may choose to withdraw or stop at any time. benefits and military significance: the proposed study will be the first of its kind to assess the efficiency of various injectable medication delivery platforms. this data will provide a background for improving injectable drug delivery practices in various setting (eg military and pre-hospital settings), including the potential to inform novel medical device development.

Eligibility criteria:
inclusion criteria: * any participant over the age of 18 able to provide consent exclusion criteria: * only participants with pre specified conditions impacting cognitive and/or manual dexterity will be excluded * recent substance use * non health care workers injection with experience with medication injection in last 12 months

Keywords: autoinjector needle syringe medication
analytical validation of the abioscope device with an ige test panel: point-of-care precision, sample type comparison and method correlation

Conditions: Allergy; Allergic Asthma; Allergy to Cats; Allergy to House Dust; Allergy to Dog Dander (Finding); Allergy Mold; Allergy Cockroach

Summary: this is a multicenter, prospective, observational study to evaluate the analytical performance of the abionic ige multi-allergen test panel on the abioscope® device in a u.s. point-of-care environment within a clinical laboratory operating under a clia certificate for tests of moderate complexity. the study will assess point-of-care ('external') precision, sample type comparison and correlation with a reference method (phadia laboratory system, thermofisher scientific).


Eligibility criteria:
inclusion criteria: * provision and understanding of signed and dated written informed consent by the subject prior to any mandatory study-specific procedures, sample collection, or analysis. * male or female, 18 years of age or older. exclusion criteria: * subject participating in another study that may influence test results. * subject taking any of the following medications: systemic steroids (inhaled or nasal steroids are allowed), anti-cytokines or cytokines, systemic interferon (injection local interferon α for the treatment of hpv is allowed), anti-ige therapy (approved or investigational) or treated with systemic chemotherapy. * history of cancer, autoimmune, or immune deficiency disease. * suffering from a hematological pathology (coagulation disorder, severe anemia) that could interfere with the blood draw procedure.

Keywords: allergy asthma point-of-care immunoassay in vitro diagnostic total ige specific allergy
a trial of cognitive training in euthymic bipolar disorder

Conditions: Bipolar Disorder

Summary: bipolar disorder (bd) is characterized by extreme changes in mood and emotion dysregulation. mood changes are episodic in nature, with distinct periods of mania, depression, and asymptomatic periods of euthymia. in addition to impairments in mood, cognitive impairments are a common feature of the disorder. these cognitive impairments persist during periods of euthymia and are associated with negative clinical and psychosocial outcomes. specifically, individuals with bd show impairments in executive functions. recent studies show that emotion regulation can be down-regulated by taxing executive functions, and it can be improved with working memory training, a specific component of executive functions. these initial studies show that emotion regulation is under executive control in healthy individuals; however, the nature of this relationship is not well understood in populations that are affected by impairments in both executive control and emotion regulation. previous work on cognitive training has not targeted specific cognitive domains with an emphasis on understanding the underlying mechanisms that promote change. moreover, well-controlled randomized control trial (rct) studies are needed in order to provide high quality evidence to inform the efficacy of cognitive training interventions for psychiatric populations. the aim of the proposed study is to use a commercially available cognitive training program to study the effects of working memory training on cognitive, clinical, and psychosocial outcomes in patients with bd. we hypothesize that training working memory will lead to improvements in cognitive and emotional functioning, leading to downstream changes that will positively impact untrained outcomes, such as mood and community functioning.


Eligibility criteria:
inclusion criteria: * male or female * age between 18 and 65 years * clinically diagnosed with bipolar disorder i or bipolar disorder ii and currently in a euthymic state * normal, or corrected to normal, vision and hearing * able to provide informed consent exclusion criteria: * meeting diagnostic and statistical manual 5th edition (dsm-5) diagnostic criteria for a current major depressive episode, manic episode, or hypomanic episode * past electroconvulsive therapy (ect) * past transcranial magnetic stimulation therapy (tms) * past 3 month history of substance abuse * diagnosed with a medical condition known to affect cognition (e.g., endocrine disease) * score less than 70 on the wechsler abbreviated scale of intelligence (wasi)

Keywords: cognitive training working memory emotion regulation
diabetic/metabolic cardiomyopathy: prevalence and phenotype

Conditions: Cardiopathy; Diabetes; Metabolic Syndrome

Summary: "little is known about the prevalence, determinants and phenotypes of the cardiomyopathy associated with diabetes and/or metabolic syndrome. the emergence of new therapies (sglt2 inhibitors) that may mitigate and even prevent the onset of heart failure offers new opportunities.the objective of this protocol is to evaluate the prevalence and phenotypes of cardiomyopathy confirmed by echography in people at high metabolic risk defined as living with diabetes or obesity."

heart failure (hf) is a frequent disease with a global prevalence of 2.3% that may culminate up to 10% in the elderly. hf is associated with poor outcomes, namely multiple recurrent hospitalizations and high mortality. it is well known for several decades that diabetes is associated with a high cardiovascular mortality, with most physicians initially focusing on coronary artery disease solely. more recently, the concept of specific diabetic and/or metabolic cardiomyopathy emerged with different phenotypes. obesity and hypertension are highly prevalent in patients with type 2 diabetes (t2d) and several studies have shown similar "diabetic cardiomyopathies" and "obese cardiomyopathies". congestive hf was found to be two to three times more frequent in patients with t2d than in those without. asymptomatic hf is underestimated by lack of systematic screening of these patients which prevent them from benefiting from early therapeutics. to our knowledge, no previous study has been made with systematic screening for hf in obese patients without obvious hf signs. several tools can be used to examine the possible presence of cardiomyopathy and/or hf. the detection of cardiomyopathy at an early, preclinical stage may be of particular interest. first, studies have demonstrated that hf management is more effective at an early stage, with some drugs being associated with a reverse remodeling. second, the class of sglt2 inhibitors has proven to reduce the risk of hospitalization for hf in high-risk patients with diabetes.

Eligibility criteria:
inclusion criteria: * adults (18 years-old or more) * at high metabolic risk: diabetes of any type and/or obesity (body mass index ≥ 30 kg/m²) * admission in the departement of diabetology-obesity-nutrition, avicenne hospital, bobigny, france * patient informed and having signed consent * patient affiliated to a social security scheme or entitled exclusion criteria: * any know cardiac disease: coronary artery disease, heart failure, cardiomyopathy, pulmonary embolism \< 6 months, pulmonary hypertension, rhythm disorders \< 6 months * blood pressure \> 180/110 mmhg * severe renal failure as defined by estimated glomerular filtration rate \< 30 ml/min * age ≥ 80 years * previous inclusion in the study * patient under guardianship curatorship * patient on ame (aide médicale d'état)

Keywords: cardiomyopathy diabetes obesity
national evaluation of patients with pik3ca-related overgrowth spectrum (pros)

Conditions: PIK3CA-related Overgrowth Spectrum; CLOVES Syndrome; Klippel Trenaunay Syndrome; Megalencephaly; MCAP; Macrodactyly; Vascular Malformations; Lymphatic Malformation; Venous Malformation

Summary: overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. the genes involved in overgrowth syndromes are not well characterized but mostly concern the pik3ca/akt/mtor pathway, a major actor of cell growth and proliferation. the mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. owing to the variability of the clinical presentation, their exact prevalence is yet unknown. in order to answer this question, the investigators team create here the first french national registry on overgrowth syndromes.

overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. the genes involved in overgrowth syndromes are not well characterized but mostly concern the pik3ca/akt/mtor pathway, a major actor of cell growth and proliferation. the mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. owing to the variability of the clinical presentation, their exact prevalence is yet unknown. in order to answer this question, the investigators team create here the first french national registry on overgrowth syndromes.

Eligibility criteria:
inclusion criteria: 1. affiliated to the french healthcare insurance system. 2. pediatric and adult patients 3. clinical diagnosis of overgrowth syndrome 4. written informed consent from adult patients and from both parents of pediatric patients. exclusion criteria: 1. person subject to a judicial safeguard measure 2. inability to give informed consent

Keywords: pik3ca related overgrowth syndrome pik3ca/akt/mtor pathway clinical diagnosis biobank patient stratification
the effects of two education strategies about insulin on patient preferences and perceptions about insulin therapy

Conditions: Type 2 Diabetes

Summary: this study compared the impact of two educational strategies (an education program versus a pamphlet) on participants preferences for insulin and their perceptions about insulin and injections after attending an educational session with a diabetes educator about insulin. main research question: among adults with type 2 diabetes who are potential candidates for insulin therapy, does an education strategy that involves a personal letter from the family physician, a presentation about insulin, and information about giving an injection, versus a pamphlet education strategy, effect: preference to accept insulin therapy; perceptions about insulin therapy; or perception about the injection?

many people with type 2 diabetes who need insulin therapy are often reluctant to start using insulin to manage their diabetes. this may be because they are worried about giving an injection and do not know enough about insulin to make an informed choice. this research is important because it will help researchers and health care providers better understand the feelings and educational support that patients need when they are thinking about starting insulin. this can help health care providers to better tailor the care they give to patients.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * have a diagnosis of type 2 diabetes mellitus in their medical chart * have suboptimal glycosylated hemoglobin (hga1c \> 7.5%) recorded in their chart as the most recent lab result * currently perform self-monitoring of blood glucose * able to understand written and spoken english exclusion criteria: * are currently using, or have previously used insulin * have cognitive, visual, hearing or other medical impairment * have terminal malignancies or dementia * have psychiatric illness not controlled with medications

Keywords: diabetes, insulin, education
study of antiepileptic drug in generalised convulsive status epilepticus

Conditions: Status; Epilepticus, Tonic-clonic

Summary: compare the efficiency of the association, first line, the intravenous levetiracetam and the intravenous clonazepam, in that of a monotherapy of clonazepam intravenous in the pre-hospital treatment of tonicoclonic generalised status epilepticus.

at this time, the prehospital treatment of the status epilepticus use some molecule ("fosphenyloine") with large contra-indications. in this case the physician is not able to know the past medical history of the patient, the biological examinations and so he can not decide which molecules he can use. the levetiracetam is a knowledge medication in the epilepsy since more than twenty years. one of specificity of the levetiracetam is to be able to be used in all situations (no clinical or biological contre-indication). this molecule seems like to be very interesting to be used in prehospital system. the goal of this study is to evaluate the association levetiracetam / clonazepam in first line in the prehospital treatment of the status epilepticus

Eligibility criteria:
inclusion criteria : * age ≥ 18 years * patient taken care by a prehospital medical team participating in the study * diagnosis of tonicoclonic generalized status epilepticus confirmed on the spot by a physician of the team. exclusion criteria : * parent or the reliable person indicated by the patient present not giving its agreement for the inclusion * pregnancy clinically detectable or known for close relations at the time of the status epilepticus * tonicoclonic generalized status epilepticus after anoxia post cardiac arrest * patient having already received another treatment for the same episode of status epilepticus * patient having already participated in the study during a previous episode of status epilepticus * patient in "latent" status epilepticus. definition : patient in the coma having epileptic demonstrations (clonisms myoclonisms) small or invalid, contrasting with permanent generalized electric seizures on the eeg * patient presenting certain diagnosis of pseudo name psychogenic seizure * patient whose neurological status requires an immediate surgery (traumatism) * patient having a hyper-responsiveness about the levetiracetam or about the other by-products of pyrrolidone or an one of the excipients * patient having a hyper-responsiveness about the clonazepam, about the benzodiazepins or about one of the other constituents of the product * patient under medical guardianship * not membership in a schema of medical assurance.

Keywords: status epilepticus generalised convulsive status epilepticus first line treatments double-blind randomized controlled trial prehospital treatment
study to evaluate the effect of torcetrapib/atorvastatin in subjects with a genetic cholesterol disorder.

Conditions: Hyperlipoproteinemia Type III

Summary: the torcetrapib project was terminated on december 2, 2006 due to safety findings. to evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

for additional information please call: 1-800-718-1021

Eligibility criteria:
inclusion criteria: * diagnosis of familial dysbetalipoproteinemia (fredrickson type iii hyperlipoproteinemia) exclusion criteria: * women who are pregnant or lactating, or planning to become pregnant. * subjects with a clinically indicated need for statin (hmg-coa reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on ldl-c and hdl-c including fibrates and nicotinic acid * subjects taking any drugs known to be associated with an increased risk of myositis in combination with hmg-coa reductase inhibitors * subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
an analysis of diabetes control in puerto rico

Conditions: Diabetes Mellitus; Arterial Hypertension; Hypercholesterolemia

Summary: project: an analysis of diabetes control in puerto rico hypothesis: this project seeks to determine the causes for: i) poor adherence to prescribed treatment by patients, ii) low compliance by providers with national guidelines iii) barriers impose by health insurance in control of diabetes mellitus iv) effectiveness of a disease management program for treatment adherence by patients.

method (s) the study will consist of three phases: i) assessment phase, ii) multimedia health education campaign for patients, providers and local health insurances for adherence improvement iii) reassessment phase. target population: phase i: 600 hispanic, male and female, residents of puerto rico with a diagnosis of type 1 and 2 diabetes mellitus older than 18 of age. phase ii: 600 patients identified in phase i with individualize health education interventions on the importance of adherence to prescribed medical treatment. 2) spanish speaking population of puerto rico, health service providers, and health insurance companies through a multimedia health education campaign. phase iii: reassessment of the 600 patients of phase i. data collection tools: i) demographic information will be obtained by an interview questionnaire. patients will be assigned a control number automatically by the data system. ii) laboratory blood samples for a1c, lipids (total cholesterol, triglycerides and hdl cholesterol), and serum creatinine. iii) a comprehensive educational adherence program with different media strategies such as: radio spots, newspaper articles, public service announcements, telemedicine services. data analysis: data will be analyzed using spss for windows.

Eligibility criteria:
inclusion criteria: * type 1 and 2 diabetic patients older tha 18 years old exclusion criteria: * 1. hemophilia. * 2. persons younger than 18. * 3. persons in research studies of some drug. * 4. persons using steroids. * 5. patients with acute infections. * 6. pregnant diabetic patients.

Keywords: diabetes mellitus
comparative efficacy of single-dose doxycycline versus standard 5- day amoxicillin treatment

Conditions: Fever

Summary: abstract: background the current practice in senegal is to use broad-spectrum antibiotics including amoxicillin and/or cotrimoxazole in case of non-malarial fevers. first-line treatment with doxycycline has cured such patients. the investgators aimed to determine the efficacy of a single dose of doxycycline compared to a 5-day amoxicillin course for the treatment of fever.

methods the investgators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of niakhar, senegal. participants were enrolled based on a body temperature \> 37.5°c, as assessed using an electronic axillary thermometer. febrile patients with a positive malaria test were excluded from the study. participants were randomly assigned (1:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. the investgators monitored participants at days 2 and 7 post-treatment. the primary outcome was cure after 7 days, defined as a body temperature \< 37.5°c. the investgators used a non-inferiority margin of 10%. this trial was approved by the national ethic committees of the senegalese ministry of health in may 2017 (0026/msas/dprs/cners, march, 7, 2016).

Eligibility criteria:
inclusion criteria: * participants over 8 years with no malaria fever exclusion criteria: under 8 years pregnanants women -